Skip to main content

Table 1 Baseline characteristics

From: Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

  All patients N = 119 (%) IB CR + PR N = 69 (%) IB SD N = 35 (%) IB PD N = 15 (%) p value
Median age at diagnosis in years (range) 64 (23–90) 66 (23–90) 63 (40–86) 64 (38–89) 0.67
Median age at ibrutinib therapy in years (range) 68 (27–91) 69 (27–90) 67 (42–86) 65 (41–91) 0.74
Gender      0.89
 Male 55 (46) 33 (48) 15 (43) 7 (47)  
 Female 64 (54) 36 (52) 20 (57) 8 (53)  
BMI      0.95
  < 30 71 (71) 43 (72) 20 (69) 8 (73)  
  ≥ 30 29 (29) 17 (28) 9 (31) 3 (27)  
 Missing 19 9 6 4  
ECOG PS at diagnosis      0.53
 0 46 (46.5) 25 (42) 13 (50) 8 (61)  
 1 47 (47.5) 32 (53) 11 (42) 4 (31)  
  ≥ 2 6 (6) 3 (5) 2 (8) 1 (8)  
Missing 20 9 9 2  
MZL subtype      0.97
 NMZL 50 (42) 28 (41) 17 (49) 5 (33)  
 SMZL 29 (24) 17 (25) 8 (23) 4 (27)  
 EMZL 40 (34) 24 (34) 10 (28) 6 (40)  
Stage at diagnosis      0.95
 1–2 19 (17) 11 (16) 6 (18) 2 (14)  
 3–4 96 (83) 56 (84) 28 (82) 12 (86)  
 Missing 4 2 1 1  
B symptoms at diagnosis      0.62
 No 81 (74) 44 (70) 25 (78) 12 (80)  
 Yes 29 (26) 19 (30) 7 (22) 3 (20)  
 Missing 9 6 3 0  
LDH higher than institutional baseline      0.80
 No 70 (71) 43 (71) 20 (74) 7 (64)  
 Yes 29 (29) 18 (29) 7 (26) 4 (36)  
 Missing 20 8 8 4  
Albumin at diagnosis      0.75
 Normal 80 (81) 49 (80) 22 9  
 Low 19 (19) 12 (20) 4 3  
 Missing 20 8 9 3  
Monoclonal protein at diagnosis      0.05
 No 49 (56) 30 (54) 17 (74) 2 (25)  
 Yes 38 (44) 26 (46) 6 (26) 6 (75)  
 Missing 32 13 12 7  
BM involvement at diagnosis      0.72
 No 32 (32) 17 (30) 10 (33) 5 (42)  
 Yes 67 (68) 40 (70) 20 (67) 7 (58)  
 Not done 20 11 5 3  
TP53 mutation/17p deletion (n = 67)*      0.99
 No 19 (28) 10 (23) 7 (47) 2 (25)  
 Yes 10 (15) 7 (16) 2 (13) 1 (13)  
 Unavailable/not tested 38 (57) 27 (61) 6 (40) 5 (62)  
Complex cytogenetics (n = 67)*      0.16
 No 57 (85) 37 (90) 17 (85) 6 (67)  
 Yes 10 (15) 4 (10) 3 (15) 3 (33)  
Primary refractory disease**      0.07
 No 89 (75) 56 (81) 25 (71) 8 (53)  
 Yes 30 (25) 13 (19) 10 (29) 7 (47)  
First-line therapy      0.47
 Rituximab 58 (49) 35 (51) 19 (54) 4 (27)  
 BR 30 (25) 16 (23) 9 (26) 5 (33)  
 R-CVP 11 (9) 7 (10) 1 (3) 3 (20)  
 R-CHOP 9 (8) 5 (7) 2 (6) 2 (13)  
 Others 11 (9) 6 (9) 4 (11) 1 (7)  
Receipt of maintenance R      0.27
 No 88 (74) 47 (68) 29 (83) 12 (80)  
 Yes 31 (26) 22 (32) 6 (17) 3 (20)  
Line of ibrutinib therapy      0.40
 Second line 54 (45) 31 (45) 16 (46) 7 (47)  
 Third line 41 (35) 27 (39) 9 (26) 5 (33)  
 Fourth line and beyond 24 (20) 11 (16) 10 (28) 3 (20)  
 Median f/up in months (range)^ 23 (1–75) 23 (1–72) 26 (3–75) 6 (3–22)  
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, BMI body mass index, ECOG PS Eastern Cooperative Oncology Group performance status, MZL marginal zone lymphoma, LDH lactate dehydrogenase, BM bone marrow, BR bendamustine rituximab, R-CVP rituximab, cyclophosphamide, vincristine, prednisone, R-CHOP rituximab, cyclophosphamide, Adriamycin, vincristine, prednisone, f/up follow-up
  2. *Only among those who had bone marrow involvement. Complex karyotype was defined as the presence of at least three chromosomal aberrations in at least two cells
  3. **Primary refractory disease: defined as progression of disease at the end of induction therapy or within 6 months of treatment completion. Among these 30 patients, 13 received rituximab, 9 received BR, 4 received R-CHOP, 3 received R-CVP, 1 received other
  4. ^Among those who are alive